RVMD · XBRL financial data

Revolution Medicines financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (RVMD's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	0	1*	0	0	0	0*	—	—	—	year only	—	—
Research and development	108	148*	118	135	152	188*	206	224	263	295*	344	395
General and administrative	16	32*	23	22	24	28*	35	41	53	67*	101	110
Total operating expenses	123	181*	141	157	176	216*	241	265	315	362*	445	505
Operating income (loss)	(123)	(180)*	(141)	(157)	(176)	(216)*	(241)	(265)	(315)	(362)*	(445)	(505)
Interest income	11	19*	24	21	20	21*	25	22	22	21*	20	36
Interest expense	—	year only	—	—	0	0*	0	1	11	12*	12	24
Other income (expense)	0	—	(3)	0	0	—	(0)	(0)	0	—	0	(0)
Income tax expense (benefit)	(4)	0*	0	0	0	(1)*	—	—	—	year only	—	—
Net income (loss)	(108)	(162)*	(116)	(133)	(156)	(195)*	(213)	(248)	(305)	(365)*	(454)	(644)
Earnings per share, basic USD per share	(0.99)	(1.14)*	(0.70)	(0.81)	(0.94)	(1.12)*	(1.13)	(1.31)	(1.61)	(1.88)*	(2.29)	(3.06)
Earnings per share, diluted USD per share	(0.99)	(1.14)*	(0.70)	(0.81)	(0.94)	(1.12)*	(1.13)	(1.31)	(1.61)	(1.88)*	(2.29)	(3.06)
Weighted average shares, basic millions of shares	109	141*	165	165	167	174*	188	189	189	194*	198	211
Weighted average shares, diluted millions of shares	109	141*	165	165	167	174*	188	189	189	194*	198	211

Fiscal quarters (RVMD's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	358	696	288	276	201	543	334	402	217	384	441	815
Marketable securities	455	1,157	1,415	1,315	1,348	1,746	1,769	1,735	1,714	1,642	1,467	3,123
Prepaid and other current assets	11	25	26	34	30	38	32	39	46	49	60	90
Total current assets	824	1,879	1,729	1,625	1,579	2,328	2,135	2,176	1,977	2,075	1,968	4,028
Property and equipment, net	20	23	24	25	25	24	27	33	33	33	31	35
Right-of-use asset	53	77	76	75	74	118	116	114	134	132	130	128
Goodwill	15	15	15	15	15	15	15	15	15	15	15	15
Total assets	984	2,062	1,908	1,808	1,763	2,558	2,365	2,430	2,252	2,355	2,254	4,323
Accounts payable	30	62	32	29	24	54	48	57	75	65	81	88
Accrued liabilities	—	—	—	—	—	—	—	—	5	5	5	—
Total current liabilities	86	144	94	105	111	164	159	185	246	290	290	354
Lease liability, non-current	57	81	80	79	78	123	121	120	142	142	140	138
Total liabilities	147	236	183	190	197	293	287	564	655	723	754	1,717
Accumulated deficit	(976)	(1,138)	(1,254)	(1,387)	(1,543)	(1,738)	(1,951)	(2,199)	(2,504)	(2,869)	(3,323)	(3,967)
Total stockholders' equity	837	1,826	1,725	1,619	1,566	2,265	2,078	1,865	1,597	1,631	1,500	2,606
Total liabilities and equity	984	2,062	1,908	1,808	1,763	2,558	2,365	2,430	2,252	2,355	2,254	4,323
Common shares outstanding (cover page) millions of shares	110	165	165	167	168	186	186	187	193	198	213	214

Fiscal quarters (RVMD's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(108)	(162)*	(116)	(133)	(156)	(195)*	(213)	(248)	(305)	(365)*	(454)	(644)
Stock-based compensation	14*	25*	16	20*	21*	22*	25	29*	31*	34*	87	67*
Net cash from operating activities	(100)*	(121)*	(161)	(128)*	(130)*	(138)*	(194)	(222)*	(207)*	(274)*	(354)	(387)*
Purchases of property and equipment	3*	2*	3	2*	4*	1*	3	7*	3*	2*	2	2*
Net cash from investing activities	77*	(380)*	(248)	108*	(21)*	(393)*	(16)	34*	25*	75*	173	(1,659)*
Proceeds from issuing common stock	0*	0*	0	0*	0*	728*	—	—	—	year only	—	—
Net cash from financing activities	1*	839*	1	8*	77*	874*	1	257*	(2)*	366*	239	2,420*
Net change in cash	(22)*	338*	(408)	(13)*	(75)*	343*	(210)	69*	(184)*	166*	57	374*

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Revolution Medicines	815	not reported	(387)*	214.3M	10.2 quarters	Q2 FY26 10-QJun 30, 2026
Biomarin Pharmaceutical	736	1,025	188*	193.7M	—	Q3 FY26 10-QSep 30, 2026
Jazz Pharmaceuticals	2,036	1,243	506*	64.2M	—	Q3 FY26 10-QSep 30, 2026
Corcept Therapeutics	99	340	143*	109.4M	—	Q3 FY26 10-QSep 30, 2026
Repligen	727	209	43*	63.9M	—	Q3 FY26 10-QSep 30, 2026
Madrigal Pharmaceuticals	515	431	121*	23.2M	—	Q3 FY26 10-QSep 30, 2026
Ionis Pharmaceuticals	350	268	566*	166.2M	—	Q2 FY26 10-QJun 30, 2026
BIO-TECHNE	265	321*	95*	156.8M	—	Q4 FY26 10-KJun 30, 2026
Exelixis	305	659	280*	244.0M	—	Q3 FY26 10-QOct 2, 2026

Not investment advice. Not affiliated with the U.S. SEC.